Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome
Status:
Terminated
Trial end date:
2020-05-25
Target enrollment:
Participant gender:
Summary
This Phase 2b/3 double-blind, placebo-controlled study will evaluate the safety,
tolerability, and effects of livoletide on food-related behaviors in patients with
Prader-Willi Syndrome (PWS).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Millendo Therapeutics SAS Millendo Therapeutics, Inc.